Europe Secondary Hyperoxaluria Drug Market, By Type (Reloxaliase, Thiazide Diuretics and Supplements), Drug Type (Prescription and Over the Counter), Population Type (Children and Adults), End User (Hospitals, Specialty Clinics, Home Healthcare and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), Country (Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Belgium, Rest of Europe) Industry Trends and Forecast to 2028
Market Analysis and Insights: Europe Secondary Hyperoxaluria Drug Market
Europe secondary hyperoxaluria drug market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 67.3% in the forecast period of 2021 to 2028 and is expected to reach USD 8,346.46 million by 2028 from USD 216.90 million in 2020. Increasing awareness regarding the disease burden and increased investment in R&D for targeted drugs for secondary hyperoxaluria are the key drivers for the secondary hyperoxaluria drug market growth.
A multi-factorial disease which effect different organs and tissues caused by absorption of high oxalate concentration due to intestinal problems is known as secondary hyperoxaluria or at extreme stage known as enteric hyperoxaluria. This disease is connected highly with the diet and malabsorption caused by some disease as ingestion of oxalate or precursor of oxalate such as vitamin C is among the major cause of the disease. Oxalobacter formigenes, a bacterium which is known to be the critical factor for secondary hyperoxaluria uses oxalate as the key energy element for completing its functional requirement, plays an important role in occurrence of the disease.
For the preventive measure, low oxalate food should be taken but in countries which have highly developed socioeconomic lifestyle such as the U.S., Europe and China, the dietary habits are not proper and the lack in dietary awareness is the major cause of secondary hyperoxaluria which is expected to drive the secondary hyperoxaluria drug market. The operating revenue is limited in case of secondary hyperoxaluria owing to the fact that less number of targeted patients leads to lesser revenue from that operating segment and is expected to act as restraint for the secondary hyperoxaluria drug market growth. The low oxalate diet is hard to maintain as people consume it directly or take the precursor of oxalate. The market provides opportunity in both the aspects whether to make an oxalate low diet or on the other hand, difficulty to maintain low oxalate diet is expected to act as an opportunity for the secondary hyperoxaluria drug market growth. The renal replacement therapy is the next step after patient ignores the medication and other nutritional products which will significantly affect the product usage for medicinal treatment and lead to increased demand of renal replacement therapy which is expected to act as a challenge for the secondary hyperoxaluria drug market growth.
The secondary hyperoxaluria drug Market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Europe Secondary Hyperoxaluria Drug Market Scope and Market Size
The secondary hyperoxaluria drug market is categorized into five notable segments which are based on the type, drug type, population type, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of type, the secondary hyperoxaluria drug market is segmented into reloxaliase, thiazide diuretics and supplements. In 2021, supplements segment is dominating in the secondary hyperoxaluria drug market as there is no targeted therapy available.
- On the basis of drug type, the secondary hyperoxaluria drug market is segmented into prescription and over the counter. In 2021, over the counter segment is dominating in the secondary hyperoxaluria drug market as among all the products available for the treatment are generally supplements.
- On the basis of population type, the secondary hyperoxaluria drug market is segmented into children and adults. In 2021, adults segment is dominating in the secondary hyperoxaluria drug market as the diagnosis for secondary hyperoxaluria in adults is usually carried out for indications of kidney stone and high oxalate excretion in the urine along with UTI.
- On the basis of end user, the secondary hyperoxaluria drug market is segmented into hospitals, specialty clinics, home healthcare and others. In 2021, home healthcare segment is dominating in the secondary hyperoxaluria drug market owing to the fact that the current treatment comprises of supplements and thiazide diuretics.
- On the basis of distribution channel, the secondary hyperoxaluria drug market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and others. In 2021, retail pharmacies segment is dominating in the secondary hyperoxaluria drug market as the numbers of these pharmacies are very high and increasing with year passing.
Europe Secondary Hyperoxaluria Drug Market Country Level Analysis
Secondary hyperoxaluria drug market is analysed and market size information is provided by the country, type, drug type, population type, end user and distribution channel as referenced above.
The countries covered in the Secondary hyperoxaluria drug market report are the Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Belgium, and Rest of Europe.
Europe is expected to grow with the highest CAGR in the forecast period as targeted treatment for secondary hyperoxaluria is in high demand. Germany is expected to dominate in the market in the Europe market. Germany is one of the leading countries which have huge market potential in Europe and better R&D scenario.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Difficulty in Maintaining Low Oxalate Diet and Regulatory Support for Approval are Creating New Opportunities in the Secondary Hyperoxaluria Drug Market.
Europe secondary hyperoxaluria drug market also provides you with detailed market analysis for every country growth in particular industry with secondary hyperoxaluria product sales, impact of advancement in the secondary hyperoxaluria drug and changes in regulatory scenarios with their support for the secondary hyperoxaluria drug market. The data is available for historic period 2019 to 2020.
Competitive Landscape and Secondary Hyperoxaluria Drug Market Share Analysis
Europe secondary hyperoxaluria drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to secondary hyperoxaluria drug market.
The major companies in the Europe secondary hyperoxaluria drug market are Celebrate Vitamins, Solgar Inc., Oystershell, GlaxoSmithKline plc, Bayer AG, Nestlé, TIENS, Amway Corp., Now Foods and Nature's Bounty. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many product launches and agreements are also initiated by the companies’ worldwide which are also accelerating the secondary hyperoxaluria drugs market.
For instance,
- In November 2020, Bayer AG announced to start a G4A Digital health partnership program with the four new start-ups with a focus on cardio metabolic and renal disease, oncology and women’s health. This partnership is to shape the future of healthcare and to support the start-ups and will increase the strategic business development for the company.
Collaboration, joint ventures and other strategies by the market players is enhancing the company market in the secondary hyperoxaluria drug market which also provides the benefit for organisations to improve their offerings for secondary hyperoxaluria drug.
SKU-